Open AccessBRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations
Author(s) -
Yuri Sheikine,
Dean C. Pavlick,
Samuel J. Klempner,
Sally E. Trabucco,
Jon Chung,
Mark R. Rosenzweig,
Kai Wang,
Vamsidhar Velcheti,
Garrett M. Frampton,
Nir Peled,
Molly Murray,
Young Kwang Chae,
Lee A. Albacker,
Hatim Husain,
James Suh,
Sherri Z. Millis,
Venkataprasanth P. Reddy,
Julia A. Elvin,
Ryan J. Hartmaier,
Afshin Dowlati,
Phil Stephens,
Jeffrey S. Ross,
Trever G. Bivona,
Vincent A. Miller,
Shridar Ganesan,
Alexa B. Schrock,
Sai Hong Ignatius Ou,
Siraj M. Ali
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.17.00172
Subject(s) - cancer research , gene duplication , medicine , kinase , lung , mutation , oncology , biology , gene , genetics
Dabrafenib and trametinib are approved for the management of advanced non-small-cell lung cancers (NSCLCs) that harbor BRAF V600E mutations. Small series and pan-cancer analyses have identified non-V600 alterations as therapeutic targets. We sought to examine a large genomic data set to comprehensively characterize non-V600 B RAF alterations in lung cancer.